SCHEMBL5002879

SCHEMBL5002879

CCOP(=O)(COS(=O)(=O)C(F)(F)F)Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.43
CA1 P00915 3/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
AKR1C3 P42330 1/20 0.39
PGK1 P00558 1/20 0.38
PGK2 P07205 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030185 0.78 CA1 (0.55) CA2CA1BCHEACHEALDH1A1
SCHEMBL4998799 0.76 CA1 (0.52) CA2CA1BCHEACHEALDH1A1
SCHEMBL5912986 0.74 CA2 (0.62) CA2CA1TSHRAKR1C3PGK1
SCHEMBL78561 0.72 CA1 (0.58) CA2CA1BCHEACHEALDH1A1
SCHEMBL17595745 0.72 CA2 (0.64) CA2CA1TSHRCYP1A2CYP2C19
SCHEMBL915525 0.71 AKR1C3 (0.59) CA2CA1BCHEACHEALDH1A1
SCHEMBL2031961 0.71 CA1 (0.56) CA2CA1BCHEACHEALDH1A1
SCHEMBL4131256 0.70 CA1 (0.55) CA2CA1BCHEACHEALDH1A1
SCHEMBL10260709 0.70 TSHR (0.30) TSHR
SCHEMBL28623371 0.69 ACHE (0.50) CA2CA1BCHEACHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
EP-1812453-A1 METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES Therapharm GmbH (CH) 2007-08-01 EP disclosed
WO-2006045546-A1 METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES THERAPHARM GMBH (CH) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives POLI, PARP1, DHPS CA2 4117/4885CA1 3452/4885BCHE 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.